

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)
Ref: STEX/OUTCOME/2023-24

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594
Date: 12.02.2024

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended on December 31, 2023.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2023 as **Annexure-A** and
- Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**



The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.45 p.m.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2023, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Month ended as on 31st Dec'2023

PART I

		Standalone						Consolidated					
		Three Month period Ended			Nine Months Ended			Year Ended			Year Ended		
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
Particulars		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Rupees in Lacs (Except per Share Data)													
1	Income from operations												
	(a) Net Sales / Income from operations	4,420.45	4,267.10	3,411.55	12,737.89	10,073.57	13,788.40	4,650.22	4,354.14	3,558.18	13,198.67	10,220.20	14,086.74
	(b) Other Income	83.05	54.98	62.87	175.95	211.57	246.22	83.05	54.98	62.87	175.95	211.57	246.22
	(c) Total Revenue	4,503.50	4,322.08	3,474.42	12,913.84	10,285.14	14,034.62	4,733.27	4,409.12	3,621.05	13,374.62	10,431.77	14,332.96
2	Expenses												
	a) Cost of Material Consumed	2,872.48	2,750.96	2,285.02	8,205.28	5,932.31	8,180.29	2,909.75	2,766.87	2,317.06	8,287.47	5,964.35	8,180.29
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(411.49)	(451.77)	(619.22)	(1,387.32)	(919.96)	(1,029.82)	(411.49)	(451.69)	(619.22)	(1,387.32)	(919.96)	(970.95)
	d) Employees Benefits Expenses	576.51	522.66	493.61	1,623.82	1,418.94	1,856.88	801.14	709.84	567.12	2,167.37	1,492.45	2,044.38
	e) Finance Cost	64.66	90.72	68.19	251.03	206.51	292.27	64.66	90.72	68.19	251.03	206.51	292.27
	f) Depreciation and Amortisation Expenses	175.94	179.62	160.13	523.53	474.38	635.35	180.49	182.31	160.13	531.88	474.38	636.66
	g) Other expenses	824.49	829.85	665.51	2,381.22	1,904.38	2,366.38	861.50	864.62	705.51	2,482.19	1,945.09	2,445.82
	Total Expenses	4,102.59	3,922.04	3,053.24	11,597.56	9,016.56	12,301.34	4,406.05	4,162.67	3,198.79	12,332.62	9,162.82	12,628.46
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	400.91	400.04	421.18	1,316.28	1,268.58	1,733.28	327.22	246.45	422.26	1,042.00	1,268.95	1,704.50
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	400.91	400.04	421.18	1,316.28	1,268.58	1,733.28	327.22	246.45	422.26	1,042.00	1,268.95	1,704.50
6	Tax Expenses												
	Current Year	98.61	119.34	78.42	342.57	262.45	369.96	98.61	119.34	78.42	342.57	262.45	369.96
	MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax Liability	25.67	(20.46)	(33.18)	(45.78)	(89.48)	(136.88)	25.62	(20.56)	(33.18)	(45.93)	(89.48)	(138.31)
	Total Tax Expense	124.28	98.88	45.24	296.79	172.97	233.08	124.23	98.78	45.24	296.64	172.97	231.65
7	Net Profit /Loss for the period from Continuing operation (5- 6)	276.63	301.16	375.94	1,019.49	1,095.61	1,500.20	202.99	147.67	377.02	745.36	1,095.98	1,472.85




Particulars	Standalone						Consolidated					
	Three Month period Ended			Nine Months Ended		Year Ended	Three Month period Ended			Nine Months Ended		Year Ended
	31.12.2023 Unaudited	30.09.2023 Unaudited	31.12.2022 Unaudited	31.12.2023 Unaudited	31.12.2022 Unaudited	31.03.2023 Audited	31.12.2023 Unaudited	30.09.2023 Unaudited	31.12.2022 Unaudited	31.12.2023 Unaudited	31.12.2022 Unaudited	31.03.2023 Audited
8 Other Comprehensive Income												
Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	276.63	301.16	375.94	1,019.49	1,095.61	1,500.20	202.99	147.67	377.02	745.36	1,095.98	1,472.85
10 Net Profit /Loss attributable to												
a) Controlling Interest								151.37	376.48	880.32	1,095.44	1,484.41
b) Non-controlling Interest								(75.25)	0.54	(134.96)	0.54	(11.56)
10 Paid up equity share capital (Rs. 10/- per share)	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11	1,265.11
11 Earning Per Share (Rs.)												
Basic	2.19	2.38	2.97	8.06	8.66	12.04	1.60	1.17	2.98	5.89	8.66	11.82
Diluted	2.19	2.38	2.97	8.06	8.66	12.04	1.60	1.17	2.98	5.89	8.66	11.82

NOTES :

- The Un-audited financial results for the quarter and Nine months ended on 31.12.2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th Feb 2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 12.02.2024

**For & on behalf of Board of Directors
Medicamen Biotech Limited**



Rahul Bishnoi
(Rahul Bishnoi)
Chairman

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



**LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE
STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015**

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019


We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and nine months ended December 31, 2023 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 013152C)
UDIN: 24080857BKFFYO3347

Place: Gurugram
Date: 12.02.2024



LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE
CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and nine months ended December 31, 2023 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited (the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statements includes the Group's share of net profit/(loss) after tax of Rs. (73.64) Lakhs for the quarter and nine months ended on December 31, 2023, as considered in the consolidated unaudited financial results, in respect of an associate, based on their interim financial information which has


RAI QIMAT & ASSOCIATES
CHARTERED ACCOUNTANTS



not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 0131582)
UDIN: 24080857-181119858

Place: Gurugram
Date: 12.02.2024